Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor

Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control g...

Full description

Bibliographic Details
Main Authors: Shih-Jie Jhuo, I-Hsin Liu, Wei-Chung Tsai, Te-Wu Chou, Yi-Hsiung Lin, Bin-Nan Wu, Kun-Tai Lee, Wen-Ter Lai
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/16/3606
id doaj-e4c575f07bf547678224fe5f3aca8afa
record_format Article
spelling doaj-e4c575f07bf547678224fe5f3aca8afa2020-11-25T03:35:53ZengMDPI AGMolecules1420-30492020-08-01253606360610.3390/molecules25163606Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 InhibitorShih-Jie Jhuo0I-Hsin Liu1Wei-Chung Tsai2Te-Wu Chou3Yi-Hsiung Lin4Bin-Nan Wu5Kun-Tai Lee6Wen-Ter Lai7Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanGraduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, TaiwanSodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control group were fed standard chow, (2) the metabolic syndrome (MS) group were fed a high-fat diet, (3) the empagliflozin (EMPA) group were fed a high-fat diet and empagliflozin 10 mg/kg daily, and (4) the glibenclamide (GLI) group were fed a high-fat diet and glibenclamide 0.6 mg/kg daily. All mice were sacrificed after 16 weeks of feeding. H9c2 cells were treated with adipocytokines from the pericardial and peripheral fat from the study groups. The delayed-rectifier potassium current (I<sub>K</sub>) and L-type calcium channel current (I<sub>Ca,L</sub>) were measured by the whole-cell patch clamp techniques. Adipocytokines from the peripheral and pericardial fat tissues of mice with MS could decrease the I<sub>K</sub> and increase the I<sub>Ca,L</sub> of cardiomyocytes. After treating adipocytokines from pericardial fat, the I<sub>K</sub> in the EMPA and GLI groups were significantly higher than that in the MS group. The I<sub>K</sub> of the EMPA group was also significantly higher than the GLI group. The I<sub>Ca,L</sub> of the EMPA and GLI groups were significantly decreased overload compared with that of the MS group. However, there was no significant difference of I<sub>K</sub> and I<sub>Ca,L</sub> among study groups after treating adipocytokines from peripheral fat. Adipocytokines from pericardial fat but not peripheral fat tissues after EMPA therapy attenuated the effects of I<sub>K</sub> decreasing and I<sub>Ca,L</sub> increasing in the MS cardiomyocytes, which may contribute to anti-arrhythmic mechanisms of sodium-glucose transporter 2 (SGLT2) inhibitors.https://www.mdpi.com/1420-3049/25/16/3606pericardial fatadipocytokinedelayed-rectifier potassium current<span style="font-variant: small-caps">l</span>-type calcium channel current
collection DOAJ
language English
format Article
sources DOAJ
author Shih-Jie Jhuo
I-Hsin Liu
Wei-Chung Tsai
Te-Wu Chou
Yi-Hsiung Lin
Bin-Nan Wu
Kun-Tai Lee
Wen-Ter Lai
spellingShingle Shih-Jie Jhuo
I-Hsin Liu
Wei-Chung Tsai
Te-Wu Chou
Yi-Hsiung Lin
Bin-Nan Wu
Kun-Tai Lee
Wen-Ter Lai
Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
Molecules
pericardial fat
adipocytokine
delayed-rectifier potassium current
<span style="font-variant: small-caps">l</span>-type calcium channel current
author_facet Shih-Jie Jhuo
I-Hsin Liu
Wei-Chung Tsai
Te-Wu Chou
Yi-Hsiung Lin
Bin-Nan Wu
Kun-Tai Lee
Wen-Ter Lai
author_sort Shih-Jie Jhuo
title Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
title_short Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
title_full Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
title_fullStr Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
title_full_unstemmed Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor
title_sort effects of secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2020-08-01
description Sodium-glucose transporter 2 (SGLT2) inhibitors were shown to decrease mortality from cardiovascular diseases in the EMPA-REG trial. However, the effects of empagliflozin (EMPA) for cardiac arrhythmia are not yet clarified. A total of 20 C57BL/6J mice were divided into four groups: (1) The control group were fed standard chow, (2) the metabolic syndrome (MS) group were fed a high-fat diet, (3) the empagliflozin (EMPA) group were fed a high-fat diet and empagliflozin 10 mg/kg daily, and (4) the glibenclamide (GLI) group were fed a high-fat diet and glibenclamide 0.6 mg/kg daily. All mice were sacrificed after 16 weeks of feeding. H9c2 cells were treated with adipocytokines from the pericardial and peripheral fat from the study groups. The delayed-rectifier potassium current (I<sub>K</sub>) and L-type calcium channel current (I<sub>Ca,L</sub>) were measured by the whole-cell patch clamp techniques. Adipocytokines from the peripheral and pericardial fat tissues of mice with MS could decrease the I<sub>K</sub> and increase the I<sub>Ca,L</sub> of cardiomyocytes. After treating adipocytokines from pericardial fat, the I<sub>K</sub> in the EMPA and GLI groups were significantly higher than that in the MS group. The I<sub>K</sub> of the EMPA group was also significantly higher than the GLI group. The I<sub>Ca,L</sub> of the EMPA and GLI groups were significantly decreased overload compared with that of the MS group. However, there was no significant difference of I<sub>K</sub> and I<sub>Ca,L</sub> among study groups after treating adipocytokines from peripheral fat. Adipocytokines from pericardial fat but not peripheral fat tissues after EMPA therapy attenuated the effects of I<sub>K</sub> decreasing and I<sub>Ca,L</sub> increasing in the MS cardiomyocytes, which may contribute to anti-arrhythmic mechanisms of sodium-glucose transporter 2 (SGLT2) inhibitors.
topic pericardial fat
adipocytokine
delayed-rectifier potassium current
<span style="font-variant: small-caps">l</span>-type calcium channel current
url https://www.mdpi.com/1420-3049/25/16/3606
work_keys_str_mv AT shihjiejhuo effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT ihsinliu effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT weichungtsai effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT tewuchou effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT yihsiunglin effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT binnanwu effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT kuntailee effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
AT wenterlai effectsofsecretomefromfattissuesonioncurrentsofcardiomyocytemodulatedbysodiumglucosetransporter2inhibitor
_version_ 1724552591177678848